AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)PRNewsWire • 04/13/22
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)GlobeNewsWire • 04/13/22
Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License AgreementGlobeNewsWire • 04/07/22
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to the New Member of the Board of Directors and Grant of Restricted Stock Units and Warrants to Employees in GenmabGlobeNewsWire • 03/29/22
Genmab Announces the Nomination of a New Member of the Company's Board of DirectorsGlobeNewsWire • 03/14/22
Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular LymphomaGlobeNewsWire • 03/08/22
Genmab Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People OfficerGlobeNewsWire • 03/01/22
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell CarcinomaGlobeNewsWire • 02/24/22
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell CarcinomaBusiness Wire • 02/24/22
Genmab A/S (GMAB) CEO Jan van de Winkel on Q4 2021 Results - Earning Calls TranscriptSeeking Alpha • 02/16/22
Genmab Announces that Janssen has Received Conditional European Marketing Authorization for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, after Failure of Platinum-baseGlobeNewsWire • 12/13/21
Genmab A/S (GMAB) CEO Jan van de Winkel on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)GlobeNewsWire • 11/04/21